Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Non-WADA blood labs get chance to test in global anti-doping programme

This article was originally published in Clinica

Executive Summary

The World Anti-Doping Agency (WADA) has approved the use of non-accredited laboratories to conduct anti-doping blood testing under its Athlete Biological Passport Program. The decision announced by the executive committee following its 8-9 May meeting in Montreal, Canada, will support a significant expansion of anti-doping testing activity in countries or regions that are underserved by the world's 35 WADA-accredited laboratories, without having to transport the samples to other regions, said the agency. Existing haematological laboratories will have to fulfil a number of criteria, including the support of at least one anti-doping organisation, valid ISO accreditation and compliance with WADA's blood testing standards.

You may also be interested in...

Sun Denied Over US Antitrust Challenge

India’s Sun Pharma has been denied leave to appeal against a US court decision rejecting the company’s bid for dismissal of a multi-district antitrust lawsuit.

Former Sandoz Executive Kellum Admits US Price-Fixing

Former Sandoz executive Hector Armando Kellum has admitted involvement in a US generic price-fixing conspiracy, the US Department of Justice has announced.

99 Days Until MDR: Time Is Running Out For Medtech As Risky, Volatile Future Looms

The last year of the run up to the full implementation of the MDR has been characterized by a flurry of new documents and measures, but industry is adamant that medtech is heading for a crisis that will impact industry and patients alike.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts